Skip to main content

BIOS Fund II, LP's Form 4 filing

IN8BIO, Inc. (INAB) · filed Aug 18, 2022

Accession no.
0001104659-22-092685
Filed
Aug 18, 2022, 8:00 PM ET
Trade date
Aug 17, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market purchases total $96.5K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
BIOS Fund II, LPCIK 0001714576Director, 10% Owner
BIOS Fund II QP, LPCIK 0001716869Director, 10% Owner
BIOS Fund II NT, LPCIK 0001728851Director, 10% Owner
BIOS Incysus Co-Invest I, LPCIK 0001740029Director, 10% Owner
Cavu Management, LPCIK 0001813270Director, 10% Owner
Cavu Advisors, LLCCIK 0001813310Director, 10% Owner
Bios Equity Partners II, LPCIK 0001813313Director, 10% Owner
Kreis Leslie W.CIK 0001813316Director, 10% Owner
BIOS Equity Partners III, LPCIK 0001831976Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 17, 2022Common StockPPurchaseAcquired+6,142$1.93+$11,854.06583,407IndirectDuplicate filing
Aug 17, 2022Common StockPPurchaseAcquired+38,035$1.93+$73,407.553,612,569IndirectDuplicate filing
Aug 17, 2022Common StockPPurchaseAcquired+5,823$1.93+$11,238.39553,110IndirectDuplicate filing

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)